预约演示
更新于：2025-10-25
Poly ICLC
聚肌胞
更新于：2025-10-25
概要
基本信息
原研机构- |
在研机构 |
权益机构- |
最高研发阶段临床2期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
关联
93
项与 聚肌胞 相关的临床试验NCT06564623
A Pilot Study of Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers
NCT06529822
Phase 1 Clinical Trial of a Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
NCT05457959
A Placebo-Controlled, Single (Participant) Blind Trial to Evaluate the Safety, Tolerability, and Early Immunogenicity of Peptide-Pulsed Dendritic Cell Vaccination With Nivolumab and Ipilimumab in Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-Mutant
100 项与 聚肌胞 相关的临床结果
登录后查看更多信息
100 项与 聚肌胞 相关的转化医学
登录后查看更多信息
100 项与 聚肌胞 相关的专利（医药）
登录后查看更多信息
2,333
项与 聚肌胞 相关的文献（医药）2026-04-01BIOMATERIALS
Lipid nanoparticles that co-deliver poly(I:C) and short peptide antigens elicit anti-tumor responses with vaccination
Article
作者: Oh, Hyuna ; Song, Yiting ; Lovell, Jonathan F ; Wu, Yun ; Jablonski, James ; Li, Qinzhe ; Zhu, Haojun ; Su, Yafei ; Zhou, Shiqi ; Luo, Yuan ; Ortega, Joaquin
Polyriboinosinic-polyribocytidylic acid (pIC) is a Toll-like receptor 3 (TLR3) agonist that has been used as a vaccine adjuvant. Here, we show that an integrated lipid nanoparticle (LNP) which co-delivers pIC together with short peptide immunogens potentiates therapeutic cancer vaccination. Ionizable lipids encapsulated pIC in the core of lipid nanoparticles via electrostatic interaction, while co-inclusion of cobalt porphyrin-phospholipid (CoPoP) allowed for display of short peptides modified with 3 histidine residues on the particle surface. Co-delivery of pIC and antigens within the same particle potently elicited antigen-specific CD8+ T cell responses, leading to effective therapeutic anti-tumor effects in both Renca and TC-1 murine tumor models. Unexpectedly, the inclusion of CoPoP in the LNP appeared to mitigate cytotoxicity induced by pIC in LNP formulations and treatments were tolerated in mice based on serum chemistry and cytokine levels.
2026-04-01BIOMATERIALS
IFN-γ and TLR agonist co-adjuvants enhance the efficacy of a lipid-PLGA hybrid nanoparticle-based oxycodone vaccine
Article
作者: Hamid, Fatima A ; Rostamizadeh, Kobra ; Marecki, Courtney ; Zhang, Chenming ; Pravetoni, Marco ; Ci, Qiaoqiao ; Qian, Zhen ; Walter, Debra L ; Bian, Yuanzhi ; DeHority, Riley
The ongoing opioid epidemic continues to drive high rates of substance use disorders (SUD), fatal and non fatal overdoses, with oxycodone being one of the most widely misused prescription opioids. Immunopharmacological strategies such as vaccines that induce drug-specific antibodies offer a non-addictive, long-lasting approach to neutralize opioids in the bloodstream and prevent their entry into the central nervous system (CNS). In this study, we evaluated the immunogenicity and efficacy of novel oxycodone vaccine formulations incorporating interferon-γ (IFN-γ), either alone or in combination with toll-like receptor (TLR) agonists, delivered via either conventional hapten-carrier conjugates or lipid-PLGA hybrid nanoparticles (hNPs). All adjuvanted formulations elicited robust anti-oxycodone IgG responses, with IFN-γ + TLR agonist combinations particularly in the hNP platform producing the highest titers and enhanced antibody affinity. Subclass analysis, performed on the hNP-based vaccines, revealed IgG1-dominant responses, with modest IgG2a induction in the TLR-adjuvanted groups, suggesting partial Th1 skewing. Pharmacokinetic studies showed significantly elevated serum and reduced brain oxycodone levels in all vaccinated animals, with the hNP-based vaccine adjuvanted with IFN-γ and R848 providing the most potent CNS protection. In the hot plate assay, all formulations significantly attenuated oxycodone-induced antinociception, with the hNP-based vaccine formulated with IFN-γ and poly I:C producing the greatest reduction. These findings demonstrate that co-delivery of IFN-γ and a TLR agonist via a nanoparticle platform enhances both the magnitude and functional quality of the immune response, supporting further development of this strategy as a promising therapeutic approach for opioid use disorder.
2025-12-31OncoImmunology
A versatile silica nanoparticle platform for induction of T cell responses – applied for therapeutic vaccination against HPV16 E6/E7-positive tumors in MHC-humanized mice
Article
作者: Günter, Manina ; Feidt, Eva ; Junglas, Ellen ; Kruse, Sebastian ; Riemer, Angelika B. ; Schlosser, Ann-Katrin ; Kübelbeck, Armin ; Blersch, Josephine ; Mier, Walter ; Fricke, Lia T. ; Zottnick, Samantha ; Grabowska, Agnieszka K. ; Förster, Jonas D. ; Autenrieth, Stella E. ; Uhl, Philipp ; Denner, Philip ; Fava, Eugenio
Therapeutic vaccines represent a promising treatment option for (pre)cancerous lesions, such as human papillomavirus-induced malignancies. They act via administration of tumor-specific antigens, leading to induction of antigen-specific cytotoxic T cell responses. However, vaccination efficiency is often limited when the antigen is administered alone, due to antigen instability and inefficient uptake by antigen-presenting cells (APCs). To address these limitations, nanoparticle-based vaccine delivery systems are currently under investigation. Here, we present a novel silica nanoparticle (SiNP)-based vaccine delivery platform that can be applied for the treatment of various diseases and cancer types. We show that surface-functionalized SiNPs are non-cytotoxic and quickly taken up by APCs. Incorporation of a linker/solubilizer sequence N-terminal of the epitope allows attachment of peptides regardless of their solubility as well as efficient processing and surface presentation by APCs. Whole-body distribution studies confirmed retention of the antigen at the injection site and decelerated excretion when connected to SiNPs. Furthermore, treatment with SiNPs, especially when combined with the adjuvant poly(I:C), resulted in activation of dendritic cells capable of priming CD8+ T cells. In C57BL/6 and MHC-humanized A2.DR1 mice, the SiNP-based vaccinations induced epitope-specific CD8+ T cells. Moreover, they exhibited anti-tumor activity and provided a survival benefit in a tumor model using HPV16 E6/E7-expressing PAP-A2 cells. Thus, the novel SiNP platform represents a promising new vehicle for therapeutic vaccine delivery.
100 项与 聚肌胞 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 转移性非小细胞肺癌 | 临床2期 | 美国 | 2024-06-04 | |
| 不可切除的实体瘤 | 临床2期 | 美国 | 2018-09-25 | |
| 结肠转移性腺癌 | 临床2期 | 美国 | 2018-01-10 | |
| 结肠转移性腺癌 | 临床2期 | 美国 | 2018-01-10 | |
| HIV感染 | 临床2期 | 美国 | 2014-04-01 | |
| 基底细胞癌 | 临床2期 | 美国 | 2013-11-01 | |
| 乳腺癌 | 临床2期 | 美国 | 2013-11-01 | |
| 皮肤鳞状细胞癌 | 临床2期 | 美国 | 2013-11-01 | |
| 头颈部鳞状细胞癌 | 临床2期 | 美国 | 2013-11-01 | |
| 结肠癌 | 临床2期 | 美国 | 2011-10-11 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 3 | 淵壓範製鑰鬱簾獵艱願 = 積鑰艱構範淵網簾範積 憲壓壓餘遞憲獵積繭製 (繭衊憲餘淵構蓋壓艱觸, 積構製鑰淵網願範繭醖 ~ 鹹艱膚築鹽壓壓鬱獵憲) 更多 | - | 2025-03-21 | |||
临床1/2期 | - | Vaccine [6MHP + neoAg-mBRAF + polyICLC] with CDX-1140 50 mcg | 壓積壓願膚範餘構遞網(膚鬱膚觸願憲憲築選憲) = limited to Grade 1 or 2 treatment-related adverse events, with no treatment-related dose-limiting toxicities 鏇積觸鹽鹽鏇築鬱範夢 (齋壓淵壓膚襯淵範夢觸 ) | 积极 | 2024-11-05 | ||
Vaccine [6MHP + neoAg-mBRAF + polyICLC] with CDX-1140 200 mcg | |||||||
临床1期 | 14 | (IMA950/Poly-ICLC Subcutaneous (subQ) + Varlilumab IV) | 網餘築廠壓顧顧夢願糧 = 壓範顧遞構廠襯襯鏇鑰 積鹹齋鹽衊築齋糧艱鬱 (鏇襯範淵獵艱夢鏇築鑰, 艱鏇醖鑰齋繭積淵醖遞 ~ 製繭範膚鏇壓遞淵衊廠) 更多 | - | 2024-06-14 | ||
網餘築廠壓顧顧夢願糧 = 鏇遞鹽艱鑰壓淵鹽醖衊 積鹹齋鹽衊築齋糧艱鬱 (鏇襯範淵獵艱夢鏇築鑰, 繭衊衊獵鬱獵選鑰壓獵 ~ 獵願夢衊襯願窪淵廠繭) 更多 | |||||||
临床1期 | 12 | 範鏇顧製醖鹹選選憲範(夢艱鹽繭餘窪鬱願遞淵) = None 簾鹹膚顧廠選夢鬱壓製 (觸網鑰窪顧壓顧鏇夢鹹 ) 更多 | 积极 | 2024-04-07 | |||
临床2期 | 23 | 蓋艱衊艱淵廠選鏇簾醖 = 壓憲衊範遞獵積簾獵願 網製範簾齋鹹鹽膚網繭 (壓鹹獵網糧憲夢網淵衊, 夢衊淵簾鬱顧範艱齋願 ~ 餘鏇鹹顧範觸網簾積鏇) 更多 | - | 2023-04-03 | |||
临床1/2期 | 10 | 膚淵鏇鏇鏇觸廠顧獵壓(齋鬱簾範齋鹹顧艱夢齋) = 選鹽鑰蓋簾窪簾醖淵簾 製壓襯範鬱夢窪鹽膚膚 (積糧膚築積襯構艱憲簾 ) 更多 | 积极 | 2022-11-01 | |||
临床2期 | - | Autologous tumor lysate-pulsed DC + Poly ICLC | 積鑰範淵觸淵膚壓衊積(淵膚鏇醖鏇齋夢窪餘鏇) = 襯構觸獵網鏇製淵壓夢 蓋鏇襯衊膚夢窪積範衊 (願餘壓製襯膚窪糧艱觸 ) | 积极 | 2020-11-09 | ||
Autologous tumor lysate-pulsed DC + Resiquimod | 積鑰範淵觸淵膚壓衊積(淵膚鏇醖鏇齋夢窪餘鏇) = 鹽憲夢壓淵遞窪觸淵鹹 蓋鏇襯衊膚夢窪積範衊 (願餘壓製襯膚窪糧艱觸 ) | ||||||
临床2期 | 14 | (A: recMAGE-A3 + AS15) | 鬱餘壓膚糧築憲膚壓齋 = 構築構窪蓋鹽觸壓夢醖 憲製餘築構醖蓋簾襯襯 (繭廠鹽繭遞淵蓋憲製鏇, 願繭糧鹹選願夢願糧壓 ~ 壓鹹鹹觸繭鏇鹹網淵範) 更多 | - | 2019-12-20 | ||
鬱餘壓膚糧築憲膚壓齋 = 夢遞醖鬱齋蓋鑰築齋糧 憲製餘築構醖蓋簾襯襯 (繭廠鹽繭遞淵蓋憲製鏇, 選願獵憲糧築糧簾遞觸 ~ 糧鹹夢繭壓醖鏇觸膚構) 更多 | |||||||
临床2期 | 66 | Placebo Comparator (Cohort A: Sentinel Group) | 糧鹹淵積選構製衊製鏇(蓋製壓選膚積願顧齋壓) = 網網鹽遞遞製獵壓簾淵 鑰廠積餘壓餘衊醖築淵 (廠壓簾鏇獵餘淵鹽淵鏇, 23780.83) 更多 | - | 2019-11-12 | ||
(Cohort B: PrEP-001) | 糧鹹淵積選構製衊製鏇(蓋製壓選膚積願顧齋壓) = 廠餘鑰艱蓋選壓醖顧艱 鑰廠積餘壓餘衊醖築淵 (廠壓簾鏇獵餘淵鹽淵鏇, 6144.84) 更多 | ||||||
临床1/2期 | 15 | 積範築齋淵鹽鹽願齋淵(製憲衊遞構繭願醖觸觸) = 觸醖齋鏇範鑰簾願窪窪 積製構膚鏇簾夢築遞遞 (顧鹽構膚積憲鹽簾簾網 ) | 积极 | 2019-04-09 | |||
Placebo | - |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用